Value Adjusted for Debt and Cash: Kezar Life Sciences (KZR)
Kezar Life Sciences (KZR) develops small molecules to combat severe autoimmune pathologies, anticipating high margins driven by patents. However, current revisions of drug trials are hindering scalability while R&D costs continue to rise. This chart confirms that the market price has fixed the Enterprise Value at -11.01. Business development relies on partnerships with laboratories to discover new treatments for cancer and immune dysfunction.
Summary analytical data breakdowns for Kezar Life Sciences (KZR)
- share price and consensus valuation forecast:
- company stock exchange capitalization indicators:
- book capitalization information:
- debt level and financial liquidity data:
Total Debt to Capital Kezar Life Sciences|KZR - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital kezarlifesciences.com|KZR - Company Debts|Debt to Book Value Kezar Life Sciences|KZR - Company Long-Term Debts|Company Short-Term Debts Kezar Life Sciences|Intermediate Coverage Ratio kezarlifesciences.com
- earnings and valuation multiples information:
Analysis of all company metrics:KZR - Kezar Life Sciences Inc.
Identifying fundamentally resilient assets requires an analysis of the total business value. The Enterprise Value metric sums market capitalization and net debt to determine the actual acquisition price of a company. For Kezar Life Sciences (KZR), this metric reflects the cost of immunotherapy development while accounting for the cash burn rate. The balance between cash and liabilities is critical when awaiting test results. By analyzing the structure and dynamics of EV, an investor assesses the financial stability of the biotech firm.
Who Kezar Life Sciences competes with
ARGX (argenx N.V.) - Full Business Value|BNTX - Total Company Value|Value Adjusted for Debt and Cash ABVX (Abivax Pharma)|ADMA Biologics (ADMA) - Total Company Value|Full Business Value PTGX (protagonist-inc.com)|IMVT (Immunovant) - Enterprise Value|KNSA: Value Adjusted for Debt and Cash|Enterprise Value GRFS|Enterprise Value Adaptive Biotechnologies Inc. (ADPT)|Total Company Value Celldex Therapeutics CLDX|Value Adjusted for Debt and Cash AUPH|BCRX - Total Company Value|Vera Therapeutics Inc (VERA) - Real Price to Acquire Entire Company|DNTH: Enterprise Value|Pharvaris Pharma (PHVS) - Enterprise Value|Real Price to Acquire Entire Company ABCL|TRML: Value Adjusted for Debt and Cash|Enterprise Value PGEN|Company Buyout Price Pharming Group NV|Total Company Value Nektar NKTR|UPB - Real Price to Acquire Entire Company|ZBIO - Total Company Value|immunome.com (IMNM) - Real Price to Acquire Entire Company|GOSS (Gossamer Bio) - Real Price to Acquire Entire Company|KalVista Pharma (KALV) - Enterprise Value|Total Company Value Septerna Corp|Business Value PVLA (Pieris Corp)|Enterprise Value SVRA|RIGL - Total Enterprise Value|Total Company Value AnaptysBio ANAB|Enterprise Value Astria Therapeutics Inc ATXS|enGene Bio - Enterprise Value|Total Enterprise Value RAPT Therapeutics Inc.|JBIO (aerovatetx.com) - Real Price to Acquire Entire Company|Full Business Value ACRS (aclaristx.com)|KYTX (Kyverna Therapeutics, Inc.) - Enterprise Value|Enterprise Value Tiziana Life Sciences Ltd.|Total Company Value Cabaletta Bio, Inc (CABA)|VTYX (Ventyx Biosciences, Inc) - Value Adjusted for Debt and Cash|Theratechnologies Inc. - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash AVTX|ELDN - Total Company Value|AGEN: Total Company Value|CLYM: Enterprise Value|ZURA - Company Buyout Price|ATYR (aTyr Pharma, Inc.) - Enterprise Value|Adagene Corp - Full Business Value|Enterprise Value IMA|STTK - Total Enterprise Value|Equillium - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash CNTB|IMUX - Total Company Value|Company Buyout Price Atara Biotherapeutics ATRA|IFRX: Enterprise Value|Real Price to Acquire Entire Company X4 Pharmaceuticals Inc.|ACET (Adicet Bio Inc.) - Enterprise Value|Celularity Corp (CELU) - Company Buyout Price|Enterprise Value INMB|BRNS - Total Enterprise Value|Total Company Value SAB Biotherapeutics, Inc. SABS|AKTX: Business Value|Enlivex Therapeutics, Ltd. - Enterprise Value|Q32 Bio Inc. (QTTB) - Real Price to Acquire Entire Company|GOVX: Enterprise Value|Total Enterprise Value edesabiotech.com (EDSA)|Total Company Value iBio|Carisma Tx (CARM) - Company Buyout Price|Total Company Value XTL Biopharmaceuticals, Ltd. (XTLB)|Enterprise Value boltbio.com (BOLT)|HCW Biologics - Real Price to Acquire Entire Company|APVO (Aptevo Therapeutics, Inc.) - Full Business Value|AIM - Total Company Value|Value Adjusted for Debt and Cash ADTX (Aditxt)|GRI Bio Corp (GRI) - Total Company Value|Full Business Value XRTX (XORTX Corp)|HIND (Vyome Holdings Inc) - Enterprise Value|REVB: Value Adjusted for Debt and Cash|Enterprise Value INDP|Enterprise Value Scinai Immunotherapeutics Ltd (SCNI)|Total Company Value CalciMedica CALI|Value Adjusted for Debt and Cash AFMD|ALLK - Total Company Value|HOOKIPA Pharma Inc. (HOOK) - Real Price to Acquire Entire Company|IGMS: Enterprise Value|iTeos Therapeutics Inc (ITOS) - Enterprise Value|Real Price to Acquire Entire Company OCEA|TCBP: Value Adjusted for Debt and Cash|Enterprise Value THRD